


SHAN *et al.*
Application No.: 09/848,990
Page 4

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Eugenia Garrett-Wackowski
Reg. No. 37,330

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
EGW:dmw

TOWNS

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at line 13 of page 5 has been amended as follows:

Figure 5 shows the location of putative LXR response elements in the human SREBP-1a and SREBP-1c upstream regions. Also shown is the nucleotide sequence (SEQ ID NO:1) of the region upstream of exon 1c, which region includes the promoter for human SREBP-1c. Putative LXR α response elements are underlined.

Paragraph beginning at line 20 of page 6 has been amended as follows:

Figure 11. The sequence of PCR primers (SEQ ID NOS:2-21) used for amplifying mouse cDNA probes.

Paragraph beginning at line 20 of page 6 has been amended as follows:

To form a chimeric receptor for use in the assay of the invention, the ligand binding domain and the DNA binding domain are linked together. Suitable methods of forming such linkages are known to those of skill in the art. For a review of methods for constructing fusion proteins between receptor ligand binding domains and DNA binding domains, *see, e.g., Mattioni et al., Methods in Cell Biology* 43(Pt A):335-352 (1994). The linkage can be done using either recombinant or chemical methods. For example, a cysteine residue can be placed at either end of a domain so that the domain can be linked to another domain by, for example, a sulfide linkage. More typically, the ligand binding domains and DNA binding domains are joined by linkers, which are typically polypeptide sequences, such as polyglycine sequences of between about 5 and

FOR OFFICIAL USE ONLY

